GlassScriptPhysician profile
Steven T Alexander
NPI 1528290665
$1,502.52
in general payments reported to CMS, 2019-2025
22 companies · $53.74 in 2025
The $53.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $138 · 2021: $392 · 2022: $40.90 · 2023: $100 · 2024: $228 · 2025: $53.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $367.74 | 2019-2023 | |
| Abbott Laboratories | $238.19 | 2021-2024 | Freestyle Libre 3, Eterna, Lamitrode |
| Amgen INC. | $226.51 | 2019-2025 | Krystexxa |
| Gilead Sciences, INC. | $165.45 | 2019-2023 | |
| Abbvie INC. | $66.52 | 2023-2025 | Vraylar |
| Amarin Pharma, INC. | $55.96 | 2019-2021 | |
| Boston Scientific Corporation | $48.63 | 2024 | Wavewriter Alpha Prime 16 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.48 | 2024 | Caplyta |
| Medtronic Vascular, INC. | $44.03 | 2019-2020 | |
| Shire North American Group INC | $33.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.57 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.81 | 2019-2020 | |
| Genentech USA, INC. | $23.06 | 2019 | |
| Esperion Therapeutics, INC. | $22.71 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.18 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.25 | 2023 | |
| Adlon Therapeutics L.P. | $15.00 | 2019 | |
| Lilly USA, LLC | $14.99 | 2025 | Zepbound |
| Glaxosmithkline, LLC. | $14.73 | 2019 | |
| Sanofi Pasteur INC. | $14.21 | 2019 | |
| Merck Sharp & Dohme LLC | $11.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.